How Epstein-Barr Virus May Trigger Lupus by Reprogramming the Immune System

A virus carried by nearly every adult may help explain why the immune system turns against the body in lupus.

Epstein-Barr virus, commonly called EBV, is best known as the leading cause of infectious mononucleosis, or “mono.” Many people acquire it during childhood without noticeable symptoms. Others develop fever, swollen lymph nodes, sore throat, and prolonged fatigue during adolescence or early adulthood.

After the initial infection passes, the virus does not completely leave the body.

Instead, EBV establishes a lifelong latent infection, hiding mainly inside immune cells known as B cells. For most people, this arrangement causes no obvious long-term problem. The immune system keeps the virus under control, and the infected cells represent only a tiny fraction of the body’s total B-cell population.

New research suggests that the situation may be very different in systemic lupus erythematosus, or SLE.

In a study published in Science Translational Medicine in November 2025, researchers developed a highly sensitive method for locating rare EBV-infected B cells. They found that these cells were substantially more common in people with lupus than in healthy controls and were concentrated within B-cell populations capable of recognizing components of the body’s own cell nuclei.

The researchers also found evidence that an EBV protein called EBNA2 can alter which genes those infected cells activate. The reprogrammed B cells begin behaving like powerful antigen-presenting cells, stimulating additional immune cells and potentially amplifying the self-directed immune attack characteristic of lupus.

The findings provide an important possible mechanism connecting a nearly universal virus with a relatively uncommon autoimmune disease.

However, the research does not yet prove that EBV is the sole cause of every case of lupus. It was a mechanistic laboratory study involving a relatively small initial patient group, and its findings will need to be reproduced in larger and more diverse populations.

The study is best understood as a major advance in explaining how EBV could drive lupus in susceptible people, rather than a final declaration that the complex disease has one universal cause.

What Is Systemic Lupus Erythematosus?

Systemic lupus erythematosus is a chronic autoimmune disease.

In a healthy immune system, immune cells distinguish between potentially dangerous foreign material and the body’s own tissues. They recognize viruses, bacteria, and other threats while generally leaving healthy cells alone.

In lupus, that distinction breaks down.

The immune system produces antibodies and inflammatory responses directed against the body’s own cellular material. These reactions can cause inflammation and damage in many parts of the body, including:

• Joints
• Skin
• Kidneys
• Blood cells
• Heart
• Lungs
• Brain
• Blood vessels

Symptoms vary widely between individuals. One person may experience joint pain, fatigue, and skin rashes, while another may develop kidney inflammation, neurological problems, or serious cardiovascular complications.

The condition commonly follows a pattern of flares and quieter periods. During a flare, symptoms and immune activity intensify. At other times, the disease may become less active.

There is currently no cure, although medicines can suppress abnormal immune activity, reduce inflammation, prevent flares, and limit organ damage. Common treatments include hydroxychloroquine, corticosteroids, immunosuppressive drugs, and biologic medicines selected according to the patient’s symptoms and affected organs.

What Causes Lupus?

Scientists have long understood that lupus is unlikely to have one simple cause.

The disease appears to develop through an interaction between:

• Genetic susceptibility
• Hormonal and biological factors
• Immune-system regulation
• Environmental exposures
• Infections
• Possibly medications or other physiological stressors

Researchers have identified dozens of genetic variants that occur more frequently in people with lupus. However, inheriting risk-associated genes is usually not enough to cause the disease by itself.

Environmental factors may provide an additional trigger in people whose immune systems are already susceptible.

Ultraviolet light, silica exposure, certain medications, hormonal influences, and infections have all been studied. Among infectious agents, Epstein-Barr virus has remained one of the strongest and most persistent candidates.

The major unanswered question was not simply whether people with lupus had encountered EBV.

Almost everyone has.

The challenge was explaining why the virus might trigger autoimmune disease in one person while remaining largely harmless in another.

What Is Epstein-Barr Virus?

EBV is a member of the herpesvirus family.

It spreads primarily through saliva, including through kissing, shared drinks, utensils, and other close contact. It can also be transmitted less commonly through blood, semen, transfusion, or organ transplantation.

About nine out of ten adults show evidence of current or previous EBV infection. After the initial infection, the virus remains inside the body in a latent state and may occasionally reactivate.

EBV primarily establishes long-term residence inside B lymphocytes.

B cells normally help protect the body by:

• Producing antibodies
• Recognizing foreign antigens
• Remembering previous infections
• Presenting antigens to T cells
• Coordinating parts of the adaptive immune response

This relationship makes B cells an effective hiding place for EBV.

The virus can remain largely inactive inside them, producing so little viral material that infected cells are exceptionally difficult to distinguish from uninfected ones.

That technical problem prevented scientists from studying the exact behavior of rare EBV-positive B cells in lupus at sufficient resolution.

The new study was designed to overcome it.

The Long-Suspected Connection Between EBV and Lupus

Researchers have associated EBV with lupus for decades.

Previous studies found that people with SLE often show:

• Higher EBV viral loads
• Evidence of abnormal viral reactivation
• Altered antibody responses to EBV proteins
• Poorer immune control of latent infection
• Antibodies that react with both viral and human proteins
• Greater immune activity involving EBV-associated pathways

Some research also suggested that EBV reactivation may occur before or alongside the transition from early autoimmune warning signs to classifiable lupus.

But those findings were largely associative.

They showed that EBV and lupus appeared together more often or behaved differently in affected individuals. They did not clearly demonstrate how a tiny population of virus-infected cells could create widespread immune dysfunction throughout the body.

The 2025 study attempted to identify that missing mechanism.

How Researchers Found the Hidden Infected Cells

The research team developed a specialized single-cell sequencing platform known as EBV-seq.

Standard single-cell RNA sequencing examines genetic activity inside individual cells. It reveals which genes are being expressed and helps researchers distinguish between different immune-cell populations.

Latent EBV presents a special difficulty because it produces extremely small amounts of viral RNA. Standard sequencing may fail to detect those signals, causing infected cells to appear uninfected.

EBV-seq added targeted probes designed to detect multiple EBV transcripts.

The researchers combined this viral detection with:

• Single-cell RNA sequencing
• Cell-surface protein measurements
• B-cell receptor sequencing
• Bioinformatic analysis
• Chromatin and gene-regulation data
• Laboratory cell-culture experiments
• Recombinant antibody testing

This enabled them to identify individual B cells carrying EBV and examine what those cells were doing differently.

The platform could detect hidden viral activity while also revealing the infected cell’s subtype, antibody receptor, inflammatory state, and gene-expression pattern.

The Study Compared Lupus Patients With Healthy Controls

In the study’s initial human comparison, researchers examined immune cells from 11 people with lupus and 10 healthy controls.

In healthy EBV-positive individuals, fewer than approximately one in 10,000 B cells carried detectable latent EBV.

Among the lupus participants, approximately one in 400 B cells was infected.

That represented about a 25-fold difference in the frequency of EBV-positive B cells.

The absolute numbers remained small.

Even in lupus, the overwhelming majority of B cells were not infected.

This created an important scientific puzzle: how could roughly one infected cell among hundreds help produce an autoimmune response involving vast numbers of uninfected immune cells?

The researchers’ experiments suggest that the answer lies in amplification.

The infected cells may act less like the entire attacking army and more like commanders that recruit and activate a much larger force.

EBV Was Concentrated in an Unusual B-Cell Population

The EBV-positive cells found in lupus were predominantly part of a memory B-cell population described as CD27-positive, CD21-low B cells.

Memory B cells normally retain information about previous infections and help the immune system respond rapidly if the same pathogen returns.

CD21-low B cells are different from typical resting memory cells. They are often associated with persistent immune activation, chronic infection, aging, and autoimmune disease.

In the lupus study, EBV-infected B cells expressed genes including:

• ZEB2
• TBX21, which produces the transcription factor T-bet
• Genes involved in B-cell activation
• Genes involved in antigen presentation
• Pro-inflammatory immune pathways

This suggested that EBV was not merely hiding passively inside random B cells.

It was associated with a distinct activated state capable of influencing other immune cells.

What Are Autoreactive B Cells?

B cells create an enormous variety of antibody receptors.

This diversity allows the immune system to recognize countless possible viruses, bacteria, toxins, and other threats.

The process is partly random, which means some newly formed B cells will inevitably develop receptors capable of binding to the body’s own molecules.

These are called autoreactive B cells.

Their existence is not automatically abnormal.

A substantial share of immature or developing B cells may show some degree of self-reactivity. Healthy immune systems use several control mechanisms to remove, silence, edit, or restrain those potentially dangerous cells.

Many remaining autoreactive cells persist in a dormant or unresponsive state.

Lupus develops when some of these safety systems fail and self-reactive B cells become activated.

They may then produce autoantibodies targeting:

• DNA
• RNA
• Histones
• Nuclear proteins
• Ribonucleoprotein complexes
• Other cellular structures

Antinuclear antibodies are a major laboratory and biological feature of systemic lupus.

The new study found that EBV appeared to be infecting and activating precisely these kinds of nuclear-antigen-reactive B cells.

The Researchers Recreated Antibodies From Infected B Cells

To determine what the infected cells were capable of recognizing, the team reconstructed antibodies from their individual B-cell receptor sequences.

Antibodies derived from EBV-infected B cells belonging to lupus patients bound to characteristic nuclear autoantigens associated with SLE.

By contrast, antibodies reconstructed from infected cells taken from healthy participants did not show the same pattern of binding to those prototypical lupus targets.

This was one of the study’s most important observations.

It suggested that EBV was not simply more abundant in the blood of lupus patients.

It was residing inside B cells whose antibody receptors were already directed toward the body’s own nuclear material.

The virus appeared to have occupied the precise cell population capable of initiating or sustaining the disease’s characteristic autoimmune response.

EBNA2 May Act as a Molecular Switch

The study identified the viral protein EBNA2 as an important part of the reprogramming process.

EBNA2 stands for Epstein-Barr nuclear antigen 2.

It is a transcriptional regulator, meaning it influences which genes inside an infected cell are turned on or off. EBNA2 does not bind DNA in exactly the same manner as a standard human transcription factor, but it interacts with cellular proteins and regulatory regions to redirect gene activity.

The researchers integrated several forms of genomic data and found EBNA2 activity near regulatory regions associated with:

• CD27
• ZEB2
• TBX21
• Antigen-presentation pathways
• Other genes elevated in the EBV-positive lupus B cells

By switching on this network, EBNA2 may help transform a normally restrained self-reactive B cell into an activated, inflammatory cell capable of communicating aggressively with the rest of the immune system.

From Antibody Producer to Immune-System Organizer

B cells are commonly described as antibody-producing cells, but that is only part of their function.

They can also act as antigen-presenting cells.

An antigen-presenting B cell captures material through its receptor, processes it, and displays fragments on its surface. T cells that recognize those fragments may then become activated.

The study found that EBV-positive lupus B cells displayed gene programs consistent with strong antigen-presenting behavior.

In laboratory experiments, the cells could stimulate peripheral helper T cells.

Those T cells could then support the activation of additional B-cell populations, including:

• EBV-negative antinuclear B cells
• Double-negative 2 B cells
• Antibody-producing plasmablasts

Most of those recruited B cells did not need to contain EBV themselves.

The virus-infected cells appeared capable of beginning an immune conversation that spread far beyond the original infected population.

A Possible Chain Reaction Behind Lupus

The mechanism proposed by the researchers can be summarized as a multistep chain reaction.

Step 1: EBV Infects a Self-Reactive B Cell

EBV establishes latency inside a B cell whose receptor recognizes nuclear material from the body’s own cells.

Step 2: Viral Proteins Alter Gene Activity

EBNA2 and related viral activity switch on human genes associated with inflammatory activation and antigen presentation.

Step 3: The B Cell Becomes a Driver Cell

The infected B cell becomes more active and presents nuclear antigens to helper T cells.

Step 4: Helper T Cells Become Activated

These T cells support and amplify immune responses directed toward the same self-antigens.

Step 5: Uninfected Autoreactive Cells Join the Response

Large numbers of additional B cells and other immune cells become activated even though they do not contain EBV.

Step 6: Autoantibodies and Inflammation Spread

Plasmablasts produce antibodies targeting nuclear material. Immune complexes, inflammatory signals, complement activation, and tissue-directed immune responses contribute to systemic disease.

This model helps explain how a very small number of infected cells could influence a much larger immune network.

The EBV-positive cells would not need to directly damage every organ.

They would only need to continually stimulate a self-perpetuating autoimmune response.

Does the Study Prove EBV Causes All Lupus?

No—not yet.

The study’s senior researcher has argued that the mechanism may apply broadly and possibly to virtually all lupus cases. That is an important scientific hypothesis, but it is stronger than the evidence currently available can definitively establish.

Several limitations require caution.

The Human Sample Was Small

The initial sequencing comparison involved 11 lupus patients and 10 healthy controls.

That is sufficient for discovering a biological mechanism, but not for proving that the same pattern appears in every lupus subtype, ethnicity, age group, disease stage, or treatment background.

The Research Was Not a Prevention Trial

The study did not prevent EBV infection and demonstrate that lupus consequently failed to develop.

Such evidence would provide a stronger test of causality.

The Cells Were Examined After Lupus Had Developed

It remains possible that lupus-related immune dysfunction allows EBV-infected cells to expand rather than the expansion occurring first.

The laboratory experiments support a disease-driving role, but the direction of the relationship still requires longitudinal confirmation.

Nearly Everyone Carries EBV

About 90% of adults have been infected, while only a small minority develop lupus.

Other susceptibility factors must therefore determine why the proposed mechanism becomes clinically important in certain people.

Lupus Is Biologically Diverse

Patients can have different autoantibodies, organ involvement, disease severity, genetic risk factors, and responses to treatment.

A single pathway may be central without explaining every detail of every patient’s disease.

Independent experts have described the work as impressive while warning that it is not the final study required to establish a universal cause.

Why Do Most People With EBV Never Develop Lupus?

This is one of the study’s most important unanswered questions.

Possible explanations include differences in:

• Genetics
• Sex-related biology
• Hormonal signaling
• EBV strain
• Age at initial infection
• Viral dose
• Immune control of latent infection
• Previous infections
• B-cell regulatory mechanisms
• Environmental exposures
• The specific B cell infected by the virus

One possibility is that only certain EBV variants efficiently activate the gene programs associated with autoreactive antigen presentation.

Another is that people with particular genetic risk variants are more vulnerable to the effects of EBNA2.

Previous research has shown that EBNA2 can interact with regions of the human genome associated with autoimmune-disease susceptibility. In someone carrying the right combination of risk variants, the viral protein may exert a stronger or more damaging effect on immune-cell behavior.

Hormones and sex-linked immune differences may also influence why lupus affects women far more frequently than men.

The most likely model remains a combination:

EBV may be a necessary or powerful trigger in many cases, but genetic and biological susceptibility determines whether that common infection progresses into rare autoimmune disease.

Does Having Mono Mean Someone Will Develop Lupus?

No.

Most people infected with EBV never develop lupus.

Having had infectious mononucleosis does not mean autoimmune disease is inevitable, and there is currently no recommendation that every person with a history of mono undergo routine lupus screening.

Symptoms such as fatigue, fever, and swollen lymph nodes during an acute EBV infection are common and usually resolve.

Medical evaluation for lupus is based on a wider pattern of symptoms and laboratory findings, potentially including:

• Persistent joint pain or swelling
• Unexplained rashes
• Photosensitivity
• Mouth or nasal ulcers
• Kidney abnormalities
• Blood-cell changes
• Chest pain related to inflammation
• Neurological symptoms
• Antinuclear antibodies
• More specific autoantibodies

Anyone concerned about persistent symptoms should consult a qualified healthcare professional rather than assuming a past EBV infection has caused lupus.

Could an EBV Vaccine Prevent Lupus?

An effective EBV vaccine could potentially become one of the most important outcomes of this research.

If EBV is required to initiate the proposed autoimmune cascade, preventing infection could reduce the incidence of lupus in susceptible individuals.

A preventive vaccine might also affect other diseases associated with EBV, including:

• Infectious mononucleosis
• Certain lymphomas
• Nasopharyngeal cancer
• Some gastric cancers
• Multiple sclerosis
• Possibly other autoimmune disorders

However, no approved vaccine currently protects against EBV infection. Candidate vaccines are being studied, but their ability to prevent lupus has not been demonstrated.

Timing creates another challenge.

Most people acquire EBV relatively early in life. A preventive vaccine may therefore need to be given during infancy or childhood, before natural exposure occurs.

A vaccine would also be unlikely to remove EBV from someone already carrying a lifelong latent infection.

Its greatest value may be prevention in future generations rather than immediate treatment of current lupus patients.

Could Researchers Remove the Infected B Cells?

Another possible strategy is selectively eliminating EBV-positive autoreactive B cells.

Current lupus therapies already include treatments that affect B cells, but they generally do not identify and remove only those carrying EBV.

Broad B-cell depletion can reduce harmful immune activity, but it can also temporarily remove useful cells responsible for normal antibody responses and immune memory.

The new mechanism suggests several more precise possibilities:

• Targeting EBV-positive B cells
• Targeting nuclear-antigen-reactive B cells
• Blocking EBNA2 activity
• Interrupting T-bet or ZEB2-related pathways
• Preventing antigen presentation by infected cells
• Blocking communication with peripheral helper T cells
• Removing specific autoreactive B-cell clones

These are future research directions, not currently established treatments.

One experimental concept discussed by the Stanford team involves extremely deep B-cell depletion followed by regeneration of new B cells from the bone marrow. The idea is that replacement cells may initially be free of EBV.

That approach would carry substantial immune risks and requires clinical testing before its safety or effectiveness can be determined. The researchers also disclosed commercial interests related to experimental therapeutic development, an important consideration when interpreting future claims.

Could Existing Antiviral Drugs Treat Lupus?

Standard antiviral medications do not reliably eliminate latent EBV from B cells.

Drugs that interfere with active viral replication may have limited effect when the virus is dormant and producing only a small number of proteins.

The mechanism described in the study is therefore not simply a matter of treating an active infection in the same way one might treat influenza or another short-term viral illness.

A successful EBV-directed lupus therapy might need to:

• Recognize latently infected cells
• Block specific latent viral proteins
• Remove infected B-cell clones
• Strengthen immune control of EBV
• Prevent the infected cells from presenting self-antigens
• Interrupt the downstream autoimmune cascade

No current evidence supports using ordinary antiviral medication independently to treat or prevent lupus outside appropriate clinical care or research.

Patients should not stop prescribed lupus medicines or seek unproven antiviral treatments on the basis of this study.

Could the Discovery Improve Lupus Diagnosis?

The research may eventually lead to new biomarkers.

Potential diagnostic or monitoring tools could measure:

• The number of EBV-positive B cells
• The proportion of infected CD27-positive, CD21-low cells
• EBNA2-driven gene activity
• T-bet or ZEB2 expression
• Antibodies made by infected B-cell clones
• Signs of EBV reactivation
• Interactions between infected cells and helper T cells

Such tests might help identify:

• People at elevated risk before full disease develops
• Patients whose lupus is strongly driven by the EBV pathway
• Individuals more likely to respond to B-cell-targeted treatment
• Changes in disease activity or treatment response

These possibilities remain speculative.

The new EBV-seq platform is a research tool rather than a routine clinical test, and it may be too complex or expensive for ordinary diagnostic use in its current form.

What the Study Means for People Living With Lupus Today

The findings do not immediately change standard treatment.

People with lupus should continue following the plan created with their rheumatologist or other specialists.

The study does not show that patients should:

• Take unapproved antiviral drugs
• Stop immunosuppressive medication
• Avoid normal contact with family members
• Attempt to “detox” EBV
• Purchase unvalidated EBV tests
• Assume every flare represents viral reactivation
• Believe that lupus can currently be cured by eliminating one infection

The practical meaning is scientific rather than immediately therapeutic.

Researchers now have a more specific biological pathway to investigate.

Instead of treating lupus only as generalized immune overactivity, future therapies may be able to target the small population of cells that initiates or sustains the wider response.

That could eventually produce treatment that is more precise and less broadly immunosuppressive.

Why the Research Matters Beyond Lupus

EBV has also been implicated in multiple sclerosis and investigated in connection with several other autoimmune diseases.

The same broad principle may apply elsewhere:

1. EBV infects a B cell with a particular self-reactive receptor.
2. Viral gene regulation changes the cell’s behavior.
3. The infected B cell becomes a powerful antigen-presenting cell.
4. It recruits a larger network of uninfected immune cells.
5. A tissue-specific autoimmune response develops.

The targeted self-antigen would differ by disease.

In lupus, it may involve nuclear material distributed throughout the body.

In multiple sclerosis, it may involve proteins associated with the brain and spinal cord.

Researchers are now investigating whether similar EBV-driven B-cell states appear in other autoimmune disorders. A related 2026 preprint reported a comparable concept involving autoreactive B cells targeting central nervous system antigens in multiple sclerosis, although that work had not yet completed peer review at the time it was posted.

Frequently Asked Questions

What did the new EBV and lupus study discover?

The researchers found that EBV-infected B cells were about 25 times more frequent among the lupus participants than among healthy controls. The infected cells were enriched in an activated memory B-cell population and showed gene programs associated with inflammation and antigen presentation.

Does Epstein-Barr virus cause lupus?

The study provides a strong possible mechanism through which EBV may drive lupus in susceptible people. It does not yet prove that EBV is the sole cause of every lupus case.

What is the DOI of the study?

The paper’s DOI is 10.1126/scitranslmed.ady0210.

When was the research published?

It was published in Science Translational Medicine on November 12, 2025.

What is EBV-seq?

EBV-seq is a specialized single-cell sequencing method developed to detect tiny amounts of viral RNA inside individual immune cells while also measuring the cells’ gene activity and biological characteristics.

How common is Epstein-Barr virus?

Approximately nine out of ten adults show evidence of current or previous EBV infection.

Why does EBV cause mono in some people?

The symptoms depend partly on the age and circumstances of initial infection. Childhood infections are often mild or unnoticed, while first infection during adolescence or young adulthood is more likely to cause infectious mononucleosis.

Does EBV ever leave the body?

No. After infection, it generally remains for life in a latent state inside certain cells, particularly B cells.

Why do most people with EBV not develop lupus?

Lupus probably requires additional genetic, hormonal, immune, and environmental susceptibility. The viral strain, infected B-cell type, and the person’s ability to control latent infection may also matter.

What are autoreactive B cells?

They are B cells whose receptors can recognize the body’s own molecules. Healthy immune systems usually remove or silence them, but in autoimmune disease they may become activated.

What is EBNA2?

EBNA2 is an EBV protein that regulates gene activity inside infected cells. The study suggests it helps activate inflammatory and antigen-presenting programs in lupus-associated B cells.

What are antinuclear antibodies?

Antinuclear antibodies bind to substances inside cell nuclei, such as DNA and nuclear proteins. They are commonly found in lupus, although a positive test alone does not prove that a person has the disease.

Did the study find EBV inside the cells producing lupus autoantibodies?

The researchers reconstructed antibodies from EBV-positive B cells in lupus patients and found that they recognized characteristic nuclear autoantigens.

Can EBV testing diagnose lupus?

No. EBV is too common for a positive antibody test to diagnose lupus. Most healthy adults test positive for evidence of previous infection.

Should people with lupus take antiviral medicine?

The study does not establish ordinary antiviral medication as a lupus treatment. Patients should use only treatments recommended by qualified healthcare professionals.

Is there an EBV vaccine?

No EBV vaccine is currently approved, although several candidates are under development or clinical investigation.

Could an EBV vaccine prevent lupus?

Potentially, but this has not been proven. Researchers would need to show that preventing EBV infection reduces later lupus incidence.

Can current lupus treatments remove EBV?

Current treatments may affect infected B cells indirectly, particularly therapies that reduce B-cell populations, but they are not approved specifically to eliminate latent EBV.

Does the study mean lupus will soon be cured?

No. The research identifies a promising mechanism and potential therapeutic targets, but developing, testing, and approving new treatments will require additional laboratory studies and clinical trials.

What should someone do if they think they have lupus?

They should speak with a healthcare professional. Lupus diagnosis usually requires a medical history, physical examination, blood and urine tests, and evaluation by a rheumatologist. There is no single test that can diagnose every case.

Final Thoughts

For decades, scientists knew that Epstein-Barr virus and lupus were connected.

People with lupus showed unusual antibody responses to EBV, poorer control of latent infection, and higher viral activity in parts of the immune system. Yet the central biological question remained unresolved.

How could a virus carried quietly by billions of people drive a severe autoimmune disease in only a small number of them?

The new study offers a compelling answer.

EBV may occasionally infect a B cell already capable of recognizing the body’s own nuclear material. Through proteins such as EBNA2, the virus can alter the cell’s gene activity, turning a normally restrained autoreactive cell into an inflammatory antigen-presenting cell.

That infected cell can then activate helper T cells and recruit many more self-reactive immune cells.

The result is an expanding response that no longer depends on every participating cell carrying the virus.

A tiny population of infected cells may therefore have an effect far larger than its numbers suggest.

This model explains several previously disconnected observations: why EBV remains associated with lupus, why B cells are central to the disease, why antinuclear antibodies develop, and why a small viral reservoir might help maintain systemic inflammation.

It also creates new possibilities.

A future vaccine might prevent the initiating infection. A targeted therapy might eliminate the dangerous infected B cells. Another treatment might block EBNA2, antigen presentation, or the communication between B cells and helper T cells.

Those possibilities are still ahead.

The current study does not prove that every lupus case begins in exactly the same way, and it does not provide an immediate cure. Its initial patient group was small, its mechanism needs independent confirmation, and researchers must still explain why nearly everyone encounters EBV while relatively few people develop autoimmune disease.

Even with those limitations, the work represents an important shift.

It moves the EBV-lupus relationship from a broad epidemiological suspicion toward a specific, testable cellular mechanism.

That is often how medical progress begins: not with an instant cure, but with a clearer understanding of which cell, which protein, and which biological conversation must be interrupted.

Research paper: “Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus,” Science Translational Medicine, 2025.

DOI: 10.1126/scitranslmed.ady0210